Baird raised the firm’s price target on Cardinal Health (CAH) to $203 from $197 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- Cardinal Health price target raised to $185 from $183 at Wells Fargo
- Cardinal Health’s Growth Potential: Buy Rating Reaffirmed Amid Strong Pharma Performance and Strategic Focus
- Cardinal Health Reports Strong Q4 and FY 2025 Results
- Cardinal Health: Strategic Acquisitions and Raised Guidance Justify Buy Rating
- Cardinal Health’s Strong Performance and Strategic Initiatives Justify Buy Rating